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ABSTRAK
Pada sepuluh tahun terakhir, perkembangan terapi target pada karsinoma sel renal bermetastasis menjadi 
harapan baru dan mampu meningkatkan prognosis penyakit tersebut. Terdapat tiga terapi target yang telah 
dikembangkan termasuk multi-targeted tyrosine kinase inhibitors (TKI), penghambat mammalian target of 
rapamycin (mTOR) complex-1 kinase, dan antibodi monoklonal humanized antivascular endothelial growth factor 
(VEGF). Tujuan artikel ini secara kritis menelaah studi terkini terapi target untuk tatalaksana pasien tersebut. 
Pada sebagian besar uji klinis yang mengevaluasi terapi target, pasien distratifikasi berdasakan model yang 
dikembangkan oleh Memorial Sloan Kattering Cancer Center (MSKCC) dan rekomendasi terapi berdasarkan 
tingkat resiko pasien. Terapi target lini pertama (belum pernah mendapatkan terapi sistemik sebelumnya), sunitinib, 
pazopanib, atau bevacizumab ditambah IFN-α merupakan pilihan terapi dengan tingkat resiko menguntugkan dan 
sedang serta gambaran histologi sel jernih. Pasien yang mengalami progresifitas pasca terapi sitokin, sorafenib 
atau axitinib adalah pilihan yang direkomendasikan. Karsinoma sel ginjal bermetastasis tipe sel jernih dengan 
tingkat resiko menguntungkan dan sedang yang gagal pada terapi target lini pertama dapat ditatalaksana dengan 
sorafenib, everolimus, temsirolimus atau axitinib. Akan tetapi, studi saat ini menunjukkan tidak ada pilihan terapi 
sekuensial terbaik pasca kegagalan terapi lini pertama. Pasien dengan tingkat risiko buruk dan gambaran histologi 
bukan sel jernih, temsirolimus merupakan terapi target yang didukung oleh uji klinis fase III. Saat ini, beberapa 
obat baru masih dalam tahap uji klinis fase II dan III dan hasil uji klinis tersebut mungkin dapat mengubah terapi 
standar pasien karsinoma sel ginjal bermetastasis di masa yang akan datang.
Kata kunci: karsinoma sel ginjal metastasis, sel jernih, terapi target, terapi sekuensial.
ABSTRACT
In the past 10 years, recent development of targeted therapy in metastatic renal cell carcinoma (mRCC) has 
provided a new hope and significantly enhanced the prognosis of the disease. Three class of targeted therapy were 
developed, including multi-targeted tyrosine kinase inhibitors (TKI), the mammalian target of rapamycin (mTOR) 
complex-1 kinase inhibitors, and the humanized antivascular endothelial growth factor (VEGF) monoclonal 
antibody. Hence, the objective of this article was to critically examine the current evidence of targeted therapy 
treatment for patients with mRCC. In the majority of trials evaluating targeted therapy, patients were stratified 
according to Memorial Sloan Kattering Cancer Center (MSKCC) risk model and the recommendation of targeted 
treatment based on risk features. In first-line setting (no previous treatment), sunitinib, pazopanib, or bevacizumab 
plus IFN-α were recommended as treatment options for patient with favorable- or intermediate- risk features and 
clear cell histology. Patients who progressed after previous cytokine therapy would have sorafenib or axitinib as 
treatment options. Clear-cell mRCC with favorable- or intermediate- risk features and failure with first-line TKI 
therapy might be treated with sorafenib, everolimus, temsirolimus or axitinib. However, the current evidence did 
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not show the best treatment sequencing after first-line TKI failure. In patients with poor-risk clear-cell and non-
clear cell mRCC, temsirolimus was the treatment option supported by phase III clinical trial. In addition, several 
new drugs, nowadays, are still being investigated and waiting for the result of phase II or III clinical trial, and 
this might change the standard therapy for mRCC in the future.
Keywords: clear cell, metastatic, non-clear cell, renal cell carcinoma, sequential therapy targeted therapy.
INTRODUCTION
Kidney cancer is one of the most common 
malignancies worldwide with 2% of all adult 
malignancies, and approximately 271.000 new 
cases were diagnosed in 2008.1-3 Approximately 
90 % of all renal malignancy are comprised 
as renal cell carcinoma (RCC).4 The incidence 
of renal tumor differs between countries, with 
the highest incidence in Australia, Europe, and 
America, and the incidence is low in India, Africa, 
and China.5 The mortality was highest in Australia, 
New Zealand, North America, and Europe, 
whereas the lowest mortality rate was in Africa 
and Asia.2 Over the last two decade until recently, 
the incidence of RCC increased approximately 
2% in Europe and worldwide, though the 
incidence decreased in Denmark and Sweden.6 
The incidence of kidney cancer in Indonesia is 
2.4-3 cases/100.000 population which increased 
from the earlier estimation approximately 1.4-
1.8 cases/100.000 population.7 Data from Cipto 
Mangunkusumo hospital between 1995 to 2014, 
total of 120 patients was diagnosed with RCC. 
Among them, 28% of  patients were present with 
nodal metastasis and 24% of patients were present 
with distant metastasis (Mochtar CA, et al, 2015, 
unpublished data).
Approximately one third of patients 
diagnosed with RCC present with metastatic 
diseases, and up to 40% of patients with clinically 
localized RCC will develop metastasis.8 Patients 
with mRCC face a fatal prognosis, with 5-year 
survival rates less than 10%.9 In the past 20 years, 
cytokine therapy using interferon-α (IFN-α) 
was standard treatment of mRCC and became 
the main focus of the research for renal cancer. 
The response rate of mRCC patient treated with 
IFN-α was less than 10% and median overall 
survival (OS) was 13 months. In several trials 
evaluated the cytokine, toxicity frequently 
occurred and required inpatient administration 
for intensive care. The limitations of cytokine 
therapy had intensified the research of a new 
class of drugs that much more specifics sites 
of cellular action than immunotherapy. Recent 
development of more specific action, called 
targeted therapy, has provided a new hope for the 
treatment of mRCC and significantly improved 
the perspective of treatment from this disease.10 
Three classes of targeted therapy have been 
developed including multi-targeted tyrosine 
kinase inhibitors (TKI): sorafenib, axitinib, 
pazopanib, and sunitinib; the mammalian 
target of rapamycin (mTOR) complex 1 kinase 
inhibitors: temsirolimus and everolimus; the 
humanized antivascular endothelial growth factor 
(VEGF) monoclonal antibody: bevacizumab with 
interferon (IFN)-α.8,11 Abundance of targeted 
agents has been approved for treatment of mRCC, 
yet the most effective treatment of mRCC is still 
unknown. Systemic targeted treatment may be life 
long and expensive, thus financial reason might 
be influence the patient compliance.12 In addition, 
current Indonesia kidney cancer guideline does 
not clearly state the targeted treatment strategy 
for mRCC patient.13 In order to improve the 
benefits of the targeted therapy, mRCC patients 
should be treated based on the risk stratification, 
histopathology, and status of previous systemic 
treatment. Hence, the aim of this article is to 
review the current evidence of targeted treatment 
and supplements the treatment strategy for mRCC 
patient in our current guideline.
TARGETED THERAPY FOR METASTATIC 
CLEAR-CELL RENAL CELL CARCINOMA
Several phase II/III trials evaluated TKI, 
VEGF monoclonal antibody, and mTOR 
for treating mRCC patients. These trials 
predominantly recruited patients with clear-cell 
RCC histology. Sunitinib, sorafenib, axitinib, 
pazopanib, bevacizumab+ IFNα were attempted 
Vol 48 • Number 4 • October 2016                                           Targeted therapy for metastatic renal cell carcinoma
337
for clear cell mRCC patients with favorable- or 
intermediate-risk feature. Temsirolimus was 
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evaluated in phase III clinical trial for poor risk 
features (Table 1).
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Patient Risk Stratification
The Prognostic model to predict survival of 
mRCC patients  was important for interpreting 
and designing a clinical trial. An ideal prognostic 
model must be easy to use and included the most 
relevant disease characteristics. There were 
several prognostic models, which predicted the 
patient survival and influenced the choice of 
targeted treatment. Memorial Sloan Kattering 
Cancer Center (MSKCC) and Groupe Francais 
d’Immunotherapie were calculated the prognostic 
model based on the outcome of patient treated 
with immunotherapy, especially IFN-α and 
Interleukin-2 (IL-2).14-16 Since the IFN-α was 
a considered as a suitable comparator of a new 
drug , the prognostic model that used for clinical 
trial should be derived from the population 
of mRCC patient treated with IFN-α therapy. 
MSKCC model was the first prognostic model 
to predict survival of patients in interferon era, 
and was used in the majority of trials to evaluate 
the targeted treatment. MSKCC risk system 
stratified patients with poor-, intermediate-, and 
favorable-risk categories based on the number of 
clinical features and laboratories (Table 2).14,15
five agents as first line therapy i.e sunitinib, 
pazopanib, sorafenib, axitinib, and bevacizumab 
+ IFNα (Table 1). Four of these trials were using 
IFN-α as comparator, and one trial was using 
placebo as comparator, and two trials were using 
another TKI as comparator. The majority of 
trials included patients without prior systemic 
therapy. Three trials included the patients with 
prior systemic immunotherapy using IFN-α or 
IL-2. Choosing between sunitinib and pazopanib 
as the first line therapy was still controversial, 
and two trials were performed to evaluate the 
efficacy between two agents.
Sunitinib. The first Phase-III trial in 750 
showed that patients treated with sunitinib had 
longer PFS (11 month vs. 5 month) than IFN-α 
group.17 Median OS of this study was 26.4 
months for sunitinib group and 21.8 months 
in IFN-α group (HR 0.82, 95% CI 0.67 – 1.00, 
p= 0.051). Patients included in this study were 
predominantly favorable (n=264; 35.2%) or 
intermediate (n=421; 56.1%) according to 
MSKCC risk features.17,18 Analysis of large 
sunitinib global expanded-access study, a 
population based study that included a total of 
4,543 patients from 50 countries treated with 
sunitinib, showed that median OS was 18.4 
months and 19.0 months in the patients with 
or without prior cytokine therapy, respectively. 
The median PFS was 9.3 and 9.7 months in the 
patients with or without prior cytokine therapy.19 
Other cohort study in different population 
setting showed different median OS with 33.1 
months and 17.3 months in the Japan and 
Canada population.20,21 Data from RenIs (Renal 
Information System), a epidemiological database 
for patients treated with targeted therapy in 
Czech Republic, showed a small difference 
of PFS between patient in the population and 
clinical trials (10 months vs. 11 months).22
There are many factors that influence the 
effects of sunitinib (Table 3). The reduction of 
OS was significantly associated with six factors 
including Eastern Cooperative Oncology Group 
(ECOG) performance status >1, time from 
diagnosis to treatment <1 year, hemoglobin 
<lower limit of normal (LLN), calcium >upper 
limit of normal (ULN), neutrophil count >ULN, 
platelet count >ULN. Grassi et al showed that 
Table 2. Memorial sloan kattering cancer center (MSKCC) 
criteria
Risk factors* Cut-off point used
Karnofsky performance 
status
<80
Time from diagnosis to 
treatment
<12 months
Hemoglobin <LLN
LDH >1.5 times ULN
Corrected serum calcium >10.0 mg/dl (2.4 mmol/L)
*Favorable (low) risk: no risk factors;  Intermediate risk: 
one or two risk factors; Poor (high) risk: three or more 
risk factors
LDH = lactate dehydrogenase; LLN = lower limit of 
normal; ULN = upper limit of normal
Targeted Therapy for  Favorable- to 
Intermediate- risk Clear Cell mRCC
First line targeted therapy. Most of the 
trials recruited patients with favorable- or 
intermediate- risk group based on MSKCC risk 
model. Data from 7 randomized controlled trial 
(RCT) were used to determine the efficacy of 
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liver metastasis treated with sunitinib had poor 
outcome. From a series of patients treated with 
sunitinib in Japan, C-reactive protein (CRP) 
≥1 mg/dl, MSKCC poor calcification, liver 
metastasis were associated with a decrease of 
OS.19,21,23 Izzedine et al showed that OS might 
improve when mRCC patient with hypertensive 
disease treated with sunitinib and angiotensin 
inhibitors.24
Another important thing in patient with 
palliative setting beside OS was health-related 
quality of life (HRQL). Patient with improvement 
OS should have improvement quality of life. 
Analysis from Phase III trial compared sunitinib 
and IFN-α, the study found that HRQL was 
significantly better in the sunitinib group 
than IFN-α group. HRQL was measured by 
Functional Assessment of Cancer Therapy-
Kidney Symptom Index-15 item (FKSI-15) and 
FKSI Disease-Related Symptoms (FKSI-DRS).17 
Sunitinib had higher Quality Adjusted Life Years 
(QALYs) compared to IFN-α, 1.99 QALYs vs. 
1.33 QALYs. However, the incremental cost for 
one QALYs was still expensive, approximately 
$ 52,593 (IDR 734,618,108).25 When sunitinib 
was compared to best supportive care (BSC), 
patient treated with sunitinib had higher QALY 
than BSC, 1.36 QALYs vs. 0.39 QALYs. For 
one extra QALY, there was incremental cost 
approximately €34,196 (IDR 523,280,336) per 
QALY gained.26
Pazopanib. Strernberg et al performed Phase 
III clinical trial and randomized 435 patients 
with predominantly favorable- (n=170, 39%) 
or intermediate- (n=236; 54%) risk factor. This 
trial included the patients who had or had not 
been treated with cytokine therapy. The result 
of this trial showed that patients treated with 
Table 3. Factors associated with reduced OS in mRCC patients treated with Sunitinib
Study Parameters HR 95% CI
Gore et al (2015)31 ECOG PS >1 2.2 1.98-2.44
Time from diagnosis to 
treatment < 1 year
1.32 1.21–1.44
Hemoglobin < LLN 1.84 1.68–2.01
Calcium > ULN 1.41 1.25–1.59
Neutrophil count  > ULN 2.03 1.83–2.25
Platelet count > ULN 1.36 1.23–1.50
Mizayaki et al (2015)33 Poor MSKCC clasification 1.73 n.p
C-reactive protein ≥1.0mg/dl 2.80 n.p
Liver metastasis 2.37 n.p
Izzedine et al (2015)36 Hypertension patients 
treated with angiotensin 
inhibitors
0.55 0.35-0.86
Motzer et al (2013)39 White race 0.34 0.13-0.88
Bone metastasis 2.34 1.28-4.29
Baseline corrected Ca > 10 
mg/dl
4.36 1.66-11.44
Patil et al (2010)40 ECOG PS > 1 1.52 1.11-2.09
Time from diagnosis to 
treatment < 1 year
1.70 1.25-2.33
LDH 2.01 1.54–2.62
Corrected Ca level 1.58 1.30–1.86
Normal hemoglobin level 0.14 0.04-0.44
Bone metastasis 1.46 1.08-1.99
HR = hazard ratio; CI = confident interval; ECOG PS = Eastern Cooperative Oncology Group Performance Status; LLN = 
lower limit of normal; ULN = upper limit of normal; Ca = calcium; MSKCC = Memorial Sloan Kattering Cancer Center; n.p 
= not presented
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pazopanib had longer PFS compared with 
placebo (median PFS 11.1 vs. 2.8 month). 
However, pazopanib treatment did not showed 
a statistically significant improvement in median 
OS compared with placebo (22.9 months vs. 
20.5 months, in pazopanib and placebo arm, 
respectively). Diarrhea, hypertension, and nausea 
were the most common adverse effects observed 
in pazopanib arm.27,28
Sorafenib. In Phase II trial, which evaluated 
sorafenib as first line therapy, patient treated 
with sorafenib had similar PFS as treated with 
IFN-α (approximately 5.7 months). Because of 
this findings, there was not any phase III trial 
which performed for evaluating sorafenib as 
the first-line therapy. However, greater numbers 
of patients showed regression of tumor size in 
sorafenib arm (68.2% vs. 39.0%).18 Different 
result was found when sorafenib was used for 
patients with unsuccessful cytokine therapy. 
Sorafenib showed effects on prolongs the 
median PFS compared to placebo, 5.5 months 
in sorafenib arm and 2.8 months in placebo arm. 
There was no statistically significant difference 
between sorafenib and placebo for prolonged the 
median OS.29,30 Propocio et al assessed sorafenib 
as first line and second line therapy in community 
setting, and found that the efficacy of sorafenib 
was generally as good as in clinical trial, 
especially when sorafenib was used as second 
line.  Patients treated with sorafenib as first line 
had median OS 17.2 months and the second 
line had median OS 16.3 months. This study 
suggested that sorafenib might be used as first 
line and second line setting, although the result 
from clinical trial, which assessed sorafenib as 
first line therapy, showed no difference compared 
with IFN-α.31
Axitinib. Phase III trial evaluated the efficacy 
of axitinib compared with sorafenib in mRCC 
patients. In the subgroup analysis of patients 
who progressed with cytokine therapy, axitinib 
was statistically significant in prolonged median 
PFS, 12.1 months in axitinib arm vs. 6.5 months 
in sorafenib arm, but there was no statistically 
significant in prolong the OS.32,33
Bevacizumab plus IFN-α. There were two 
trials that evaluated the efficacy of combination 
bevacizumab +IFN-α compared to IFN-α alone. 
Rini et al recruited 732 patients who treated with 
bevacizumab plus IFN-α or IFN-α alone, and 
found better results for PFS in bevacizumab 
plus IFN-α group than IFN-α mono-therapy 
(8.5 vs. 5.2 month). OS between two groups 
was no statistically different  (18.3 vs. 17.4 
months).34 Other trial from Escudier et al 
showed statistically different of PFS outcome 
in bevacizumab plus IFN-α arm vs. placebo plus 
IFN-α (10.2 vs. 5.4 months).35
Comparison between first-line therapy. 
Several studies evaluated the efficacy of targeted 
therapy compared with IFN-α or placebo, whereas 
just pazopanib and sunitinib was compared 
in head-to head trial.17,28,36,37 Two randomized 
clinical trial, COMPARZ (Comparing the 
Efficacy, Safety and Tolerability of Pazopanib 
versus Sunitinib) and PISCES (Patient Preference 
Study of Pazopanib versus Sunitinib in Advanced 
or Metastatic Kidney Cancer) study, had been 
conducted to determine treatment options 
between sunitinib and pazopanib as first line 
targeted therapy. COMPARZ trial showed 
the non-inferiority comparative effectiveness 
between pazopanib 800 mg once daily continuing 
dose and sunitinib once daily dose of 50 mg for 
4 weeks followed by 2 weeks without treatment. 
Disease-progression events developed in 60% of 
patients (336 of 557) in pazopanib arm and 58% 
patients (323 of 553) in sunitinib group. The non-
inferiority of pazopanib compared with sunitinib 
are also observed in PFS outcome (median PFS 
10.2 months in sunitinib group vs. 10.5 months 
in pazopanib group).38 Even tough the survival 
rate of sunitinib and pazopanib was similar, these 
agents might be different in the incidence of 
toxicities that influenced health-related quality-
of-life (HRQoL), and this circumstance should 
be considered in palliative setting. The PISCES 
study was designed using crossover method to 
assess patient’s preference either pazopanib or 
sunitinib. This study reported that more patients 
were prefer using pazopanib  (70% of patients) 
than sunitinib  (22%), with HRQoL and safety 
as independent influencing factors.39
Milis et al40 conducted a meta-analysis of 
trial to evaluate the effectiveness of targeted 
therapy by using adjusted indirect comparison. 
They found the superiority of sunitinib compared 
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with bevacizumab plus IFN-α (HR 0.75, 95% CI 
0.60-0.93, p = 0.001) and sorafenib (HR 0.58, 
95% CI 0.38 to 0.36, p = 0.001) to improve the 
PFS. In addition, there was no difference between 
bevacizumab and sorafenib in prolong the OS.
Hence, we recommended that sunitinib, 
pazopanib, and bevacizumab plus IFN-α were 
used for mRCC patient in first-line setting 
(no previous systemic treatment). In addition, 
sorafenib and axitinib were recommended for 
patient with previous immunotherapy (with 
IFN-α or IL-2).
Sequential treatment after progressed with 
first-line therapy. Most patients experienced 
disease progression with targeted therapy, and 
sequential therapy with different agents might 
be clinically benefits. However, choosing the 
sequence of TKI remained clinical challenge. 
The rationale of using sequential therapy for 
treating progressing mRCC was evaluated in 
several trial including: RECORD-1 (Renal 
Cell cancer treatment with Oral RAD001 given 
Daily); INTROSECT (Investigating Torisel As 
Second-Line Therapy); SWITCH (Efficacy and 
Safety of Sorafenib Followed by Sunitinib Versus 
Sunitinib Followed by Sorafenib in the Treatment 
of First-Line Advanced mRCC); RECORD-3; 
AXIS (Axitinib as Second-Line Therapy for 
Metastatic Renal Cell Cancer). (Table 4)
RECORD-1 trial. Motzer et al conducted 
the first randomized trial of sequential targeted 
therapy in progressing mRCC patients who got 
targeted therapy with sunitinib or sorafenib. 
They randomized 416 patients to receive oral 
everolimus 10 mg per day or placebo. Majority 
of patients in this study were favorable- or 
intermediate- risk factors. The main outcome was 
PFS using RECIST criteria based on radiology 
evaluation. This study showed a statistically 
difference of PFS between everolimus arm and 
placebo arm with median PFS, which was 4.9 
months versus 1.9 months respectively (HR 0.33; 
p<0.001). However, there was no statistically 
significant difference OS in everolimus and 
placebo arm. This study concluded the efficacy 
and safety of everolimus in patients with mRCC 
after progression of sunitinib or sorafenib.41
INTROSECT trial. This trial compared the 
efficacy of temsirolimus and sorafenib as second 
line therapy after progression on sunitinib. This 
study were randomly assigned 512 patients 
to receive 25 mg once weekly intravenous 
temsirolimus or oral sorafenib 400 mg twice 
per day. The trial found that there was no PFS 
advantage between temsirolimus and sorafenib, 
with median PFS in temsirolimus arm was 4.3 
months compared with 3.9 months in sorafenib 
arm. However, in OS outcome, there was a 
significant difference between median OS of 
sorafenib arm compared to temsirolimus arm, 
16.6 months vs. 12.3 months, respectively. The 
longer OS suggested that the usage of sequence 
VEGF inhibitor might have benefits in patients 
with mRCC.42
SWITCH trial. This trial was the first 
prospective phase III-RCT that evaluated the 
sequential therapy with sorafenib-sunitinib (So-
Su) or sunitinib-sorafenib (Su-So) in advanced/ 
mRCC. From the total of 365 patients included in 
this study, 182 patients were randomly assorted 
into So-Su arm and 183 patients into Su-So 
arm. Median first-line PFS showed similarity 
between two groups, but median second-line PFS 
was longer in So-Su than Su-So. Total PFS and 
OS was no difference between to study group. 
The study concluded that both of treatment 
options were similarly effective in patients with 
advanced/mRCC.43
RECORD-3 trial. This trial evaluated the 
sequential therapy with first-line everolimus and 
second-line sunitinib versus first-line sunitinib 
and second-line everolimus. The total of 471 
patients with metastatic clear cell or non-clear 
cell RCC enrolled in this Phase-II clinical trial, 
238 patients randomly assigned into everolimus-
sunitinib and 233 patients into sunitinib-
everolimus arm. The primary end point of this 
study was median OS and PFS. The median 
combined PFS was not statistically different 
between two arms which the median PFS was 
21.1 months for everolimus-sunitinib arm and 
25.8 months for sunitinib-everolimus arm (HR 
1.3; 95% CI 0.9 – 1.7). There was no statistically 
difference between two arms for prolonged OS.44
AXIS trial. Seven hundred twenty three 
patients were evaluated after progressed with 
first line treatment with sunitinib, temsirolimus, 
cytokines, or bevacizumab plus IFN-α. They 
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Table 4. Sequential therapies and their impact on metastatic renal cell carcinoma
Clinical Trial Treatment groups Study design Study eligibility
N 
(patients)
Median PFS 
(months)
Median 
OS 
(months)
RECORD-145,46
Sunitinib/sorafenib-
everolimus vs. 
sunitinib/sorafenib-
placebo
Randomized 
open label 
study
 - Clear-cell mRCC 
patients 
 - Progressed on 
sunitinib or sorafenib
410 (272 
vs. 138) 4.0 vs. 1.9*
14.8 vs. 
14.4
INTROSECT47
Sunitinib-
temsirolimus vs. 
sunitinib-sorafenib
Randomized 
open label 
study 
 - Metastatic RCC 
patients (any 
histology)
 - Progressed after 
sunitinib as first line 
therapy
512 (259 
vs. 253) 4.3 vs. 3.9
12.3 vs. 
16.6*
SWITCH48
Sorafenib-sunitinib 
vs. sunitinib-
sorafenib
Randomized 
open label 
study
 - Metastatic RCC (all 
histology) 
 - No prior systemic 
therapy 
365 (182 
vs. 183)
12.5 vs. 14.9† 
(5.9 vs. 8.5†† 
g 5.4 vs. 
2.8†††)
31.5 vs. 
30.2†
RECORD-349
Everolimus-sunitinib 
vs. sunitinib-
everolimus
Randomized 
open label 
study 
 - Metastatic clear cell or 
non-clear cell RCC 
 - No previous systemic 
therapy
471 (238 
vs. 233) 25.1 vs. 25.8
† 22.4 vs. 
23.8†
AXIS26,27
Sunitinib – axitinib 
vs. sunitinib - 
sorafenib
Double blind-
RCT
 - Metastatic clear-cell 
RCC
 - Progressed after 
sunitinib as first line 
therapy
389 (94 
vs. 195) 4.8 vs. 3.4*
15.2 vs. 
16.5
Bevacizumab 
– axitinib vs. 
bevacizumab - 
sorafenib
Double blind-
RCT
 - Metastatic clear-cell 
RCC 
 - Progressed after 
bevacizumab as first 
line therapy
59 (29 vs. 
30) 4.2 vs. 4.7
14.7 vs. 
19.8
Temsirolimus- 
axitinib vs. 
temsirolimus - 
sorafenib
Double blind-
RCT
 - Metastatic clear-cell 
RCC Progressed after 
temsirolimus as first 
line therapy
24 (12 vs. 
12) 10.1 vs. 5.3
18.0 vs. 
8.5
TKI = tyrosine kinase inhibitors; N = number of patients; PFS = progression free survival; OS = overall survival; vs.= versus; 
RCT = randomized controlled trial; *= statistically significant; †= combined median OS/PFS after first-line and second line 
†† = median first-line PFS/OS;  †††= median second-line PFS/OS.
compared the axitinib 5 mg twice daily with 
sorafenib 400 mg twice daily. PFS is the primary 
end point using RECIST criteria. The secondary 
outcomes were OS, objective respond rate, and 
disease progression. Among 723 patients, 361 
patients assigned to axitinib arm and 362 patients 
assigned to sorafenib arm. The median PFS was 
6.7 months in axitinib arm compared with 4.7 
months in sorafenib arm (HR 0.665; 95% CI 
0.544-0.812; one sided p<0.001). Axitinib was 
superior compared to sorafenib for the PFS in 
patients with previously treated with sunitinib. 
There was no difference in OS data, which 
median OS 20.1 months in axitinib arms and 
19.2 months in sorafenib arm (HR: 0.969; 95% 
CI: 0.800-1.174, p = 0.374). In the subgroup 
analysis of patients previously treated with 
sunitinib, bevacizumab, and temsirolimus, the 
study did not record any statistically significant 
difference either in sunitinib or axitinib for 
prolong the OS.32
Therefore, according to these trials 
reviewed, it concluded that any sequential 
therapy has similar effects on prolong PFS 
and OS.  Sorafenib, everolimus, temsirolimus, 
and axitinib might be useful for patients who 
progressed after first line TKI. In addition, 
axitinib was superior than sorafenib in term of 
prolonged PFS, but not prolonged OS  of patients 
who progressed after first line targeted treatment.
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Targeted Therapy for Poor-risk Metastatic 
Clear Cell Carcinoma
The efficacy of targeted therapy, especially 
temsirolimus, in treating mRCC with poor-risk 
category was evaluated in Phase-III conducted by 
Hudes et al. They randomly assigned 626 patients 
to receive 25 mg of intravenous temsirolimus, 
3 million U of IFN-α subcutaneous three times 
weekly, or the combination therapies with 15 mg 
of temsirolimus weekly plus 6 million U of IFN-α 
three times weekly. The comparison between 
temsirolimus mono-therapy and IFN-α mono-
therapy illustrated that the OS was statistically 
significant with median OS 10.9 months in 
temsirolimus group versus 7.3 months in IFN-α 
group (HR 0.73, 95% CI: 0.58-0.92, p = 0.008). 
The combination of temsirolimus and IFN-α did 
not show a significant improvement of OS and 
showed a greater risk of toxicity than mono-
therapy subgroup. In addition, this study showed 
the difference of median PFS in the IFN-α, 
temsirolimus, and combination-therapy: 1.9 
month, 3.8 month, and 3.7 months, respectively.45
Temsirolimus was better tolerated than IFN-α 
with the grade 3 and 4 adverse events lower in 
the temsirolimus group (67%) than in the IFN-α 
group (78%). Although, grade 3 and 4 metabolic 
alteration (hypertriglyceridemia, hyperglycemia, 
and hypokalemia) and cutaneous rash were more 
common in temsirolimus group compared with 
IFN-α. Asthenia, pyrexia, and neutropenia were 
more frequent in the IFN-α group. Treatment 
discontinuations due to adverse event were lower 
in temsirolimus group than IFN-α, 7% and 4 % 
respectively.45
Hudes et al45 is the only one Phase-III 
randomized clinical trial that evaluated the 
efficacy of targeted therapy in naïve poor-
risk mRCC patients. If temsirolimus cannot 
be administrated to poor-risk patients, the 
alternatives of therapy might be answered from 
Phase-III trial that enrolled limited number of 
poor-risk patients. In the AVOREN trial assessing 
efficacy of bevacizumab, the study included 
54 patients from 649 patients who classified 
as poor risk according to MSKCC risk score. 
Sub-group analysis of patients with poor risk 
found that there was no significant differences 
between patients treated with bevacizumab and 
bevacizumab plus IFN-α (HR: 0.87; 95% CI: 
0.48-1.56).37 The same results was reported from 
other studies evaluating the sunitinib for patients 
with poor risk group. There was no significant 
difference between OS comparing sunitinib and 
IFN-α (5.3 months in sunitinib vs. 4.0 months 
in IFN-α; HR 0.660; 95%CI: 0.360-1.207). In 
conclusion, bevacizumab plus IFN-α or sunitinib 
might be used for poor-risk mRCC patients when 
temsirolimus could not be used.17
TARGETED THERAPY FOR METASTATIC 
NON-CLEAR CELL CARCINOMA
Because of diversity in the molecular and 
genetic basis of non-clear cell type, the trial 
was performed for clear cell mRCC, might 
not be extrapolated to other histology type of 
RCC. There was no current consensus about 
appropriate first line treatment due to lack of 
level 1 evidence. Targeted treatment in non-clear 
cell RCC focused on temsirolimus, everolimus, 
sorafenib, and sunitinib.
In the ARCC (Advance Renal Cell 
Carcinoma) trial, temsirolimus was evaluated 
in 73 patients with mRCC non clear-cell type 
(37 randomized to temsirolimus and 36 patients 
to IFN-α arm).45 This study found that the 
differences OS between temsirolimus arm and 
IFN-α arm were 11.6 months and 4.3 months 
with HR 0.49; 95% CI 0.29-0.85. They also 
observed that PFS was longer in temsirolimus 
arm than IFN-α arm with median PFS in 
temsirolimus arm 7.0 months vs. 1.8 months in 
IFN-α arm (HR 0.38, 95% CI 0.23-0.62). This 
study concluded that temsirolimus had clinically 
benefits compared to IFN-α in non-clear cell 
histology.46
Escudier et al47 performed phase II trial to 
evaluate the efficacy of other mTOR inhibitor, 
everolimus, for treating 92 patients with 
metastasis non-clear cell RCC. There were 59% 
of patients receiving everolimus that had non-
progressing disease within 6 months. Median OS 
was 21 months and median PFS was 7.6 months 
with grade ≥3 adverse events including asthenia 
(10.9%), fatigue (5.4%), and anemia (5.4%).
The ESPN (Everolimus Versus Sunitinib 
Prospective Evaluation in Metastatic Non-Clear 
Cell Renal Cell Carcinoma) trial conducted 
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by Tannir et al48 was performed to evaluate 
the efficacy of everolimus or sunitinib to treat 
metastatic non-clear RCC. This study was 
multicenter randomized clinical trial with cross 
over design and used PFS as primary outcome. 
The study reported that OS and PFS showed 
advantage of sunitinib group compared with 
everolimus (16.2 months vs. 14.9 months; 
p=0.01, and 6.1 months vs. 4.1 months; p=0.25, 
respectively).
INVESTIGATIONAL AGENTS
With the advancement of knowledge of 
the molecular mechanism about RCC, several 
agents of new-targeted treatment were being 
developed for improving the survival of mRCC 
patients.49,50 Recently, the majority of phase 
II or phase III clinical trial included VEGF 
inhibition as mechanism of action to inhibit 
tumor progression. Resistance to inhibition of 
VEGF was being suggested as a reason for tumor 
progression after therapy of VEGF inhibitor, and 
dual (or multiple) pathway inhibition was being 
developed for overcoming resistance to VEGF.51 
Lenvatinib, an agent that inhibit both VEGFR 
and FGFR, has been granted by Food and Drug 
Administration (FDA) as a potential treatment 
of advance RCC based on phase II clinical 
trial conducted by Motzer et al.52 Lenvatinib 
monotherapy showed improvement of median 
PFS by 39% compared with everolimus (HR 
0.61; 95% CI 0.38-0.98; p =0.048). OS analysis 
showed better outcome in the combination 
of lenvatinib and everolimus compared with 
everolimus monotherapy.53
In the past decade, immunotherapy has been 
less studied due to the extensive development of 
VEGF- and mTOR- directed therapy. However, 
enthusiasm has been directed to immune 
surveillance due to dramatic response of 
anti PD-1 antibody in the patient of RCC.54 
Nivolumab was the most extensively studied 
PD-1 inhibitor in mRCC. Clinical phase II trial 
showed a promising efficacy of nivolumab in 
treating mRCC patients with previous anti-
angiogenic treatment. We are still waiting for the 
recent phase III trial which comparing between 
Nivolumab and everolimus in mRCC patient 
with previously treated by systemic therapy.55,56
Cabozantinib, a TKI with potent activity 
against MET gene and VEGFR 2 receptors, has 
showed clinical benefits in patients with advanced 
clear-cell RCC in a single arm trial. Phase III 
METEOR (Cabozantinib vs. Everolimus in 
Subjects With Metastatic Renal Cell Carcinoma) 
trial evaluated the efficacy of 60 mg cabozantinib 
compared with 10 mg temsirolimus, yet this trial 
is still on going.57 Other, several clinical trials 
of phase II or III such as AGS-003 (autologous 
dendritic cell immunotherapy) and MPDL3280A 
(an engineered anti-PDL1 antibody) are still in 
progress.58,59
CONCLUSION
The development of targeted therapy has 
significantly improved the perspective of 
mRCC treatment. Sunitinib, pazopanib, and 
bevacizumab have demonstrated significant 
improvement of PFS as a first line targeted 
therapy in metastatic clear cell type RCC patients 
with favorable- and intermediate- risk category. 
Clear cell mRCC patients with favorable- and 
intermediate-risk category who progressed after 
prior cytokine therapy, sorafenib, axitinib, and 
pazopanib showed improvement of PFS. There 
was no difference on prolonged PFS and OS 
between sequential therapies. Temsirolimus 
showed benefit in prolonged PFS and OS in 
clear-cell poor risk category and non-clear 
cell mRCC. Several new drugs are still being 
investigated and waiting for the results of phase 
II or III clinical trial.
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